Detection and quantification of proviral HIV-1 184M/V in circulating CD4+ T cells of patients on HAART with a viremia less than 1000 copies/ml

Journal of Clinical Virology

Volumn 34, Issue 4, 2005, Pages 257-267

  Mohey, Rajesh ^a   Jørgensen, Louise B ^b   Møller, Bjarne K ^a   Black, Finn T ^a   Kjems, Jørgen ^c   Obel, Niels ^d  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Statens Seruminstitut ^*  (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Anti retroviral therapy; CD4+ T compartment; HIV drug resistance mutations; Low level viremia; Viral load

Indexed keywords

DNA; LAMIVUDINE; VIRUS DNA;

ARTICLE; CELL COMPARTMENTALIZATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; GENE AMPLIFICATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; LONG TERM CARE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROVIRUS; REAL TIME POLYMERASE CHAIN REACTION; VIREMIA; VIRUS CHARACTERIZATION; VIRUS DETECTION; VIRUS INACTIVATION; VIRUS LOAD; VIRUS MUTANT; VIRUS RESISTANCE; WILD TYPE;

ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; CROSS-SECTIONAL STUDIES; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; PROVIRUSES; VIREMIA;

EID: 27744581514     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2005.02.015     Document Type: Article

References (32)

1. T.W. Chun, D. Finzi, J. Margolick, K. Chadwick, D. Schwartz, and R.F. Siliciano In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency Nat Med 1 12 1995 1284 1290
2. T.W. Chun, L. Carruth, D. Finzi, X. Shen, J.A. DiGiuseppe, and H. Taylor Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection Nature 387 6629 1997 123 128
3. T.W. Chun, L. Stuyver, S.B. Mizell, L.A. Ehler, J.A. Mican, and M. Baseler Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy Proc Natl Acad Sci USA 94 24 1997 13193 13197
4. D. Descamps, P. Flandre, V. Calvez, G. Peytavin, V. Meiffredy, and G. Collin Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team JAMA 283 2 2000 205 211
5. N. Desire, A. Dehee, V. Schneider, C. Jacomet, C. Goujon, and P.M. Girard Quantification of human immunodeficiency virus type 1 proviral load by a TaqMan real-time PCR assay J Clin Microbiol 39 4 2001 1303 1310
6. S. Eisenberg, I. Aksentijevich, Z. Deng, D.L. Kastner, and Y. Matzner Diagnosis of familial Mediterranean fever by a molecular genetics method Ann Intern Med 129 7 1998 539 542
7. T.M. Folks, D. Powell, M. Lightfoote, S. Koenig, A.S. Fauci, and S. Benn Biological and biochemical characterization of a cloned Leu-3-cell surviving infection with the acquired immune deficiency syndrome retrovirus J Exp Med 164 1 1986 280 290
8. H.F. Gunthard, J.K. Wong, C.C. Ignacio, J.C. Guatelli, N.L. Riggs, and D.V. Havlir Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy J Virol 72 3 1998 2422 2428
9. S.M. Hammer, K.E. Squires, M.D. Hughes, J.M. Grimes, L.M. Demeter, and J.S. Currier A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team N Eng J Med 337 11 1997 725 733
10. A.J. Hance, V. Lemiale, J. Izopet, D. Lecossier, V. Joly, and P. Massip Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy J Virol 75 14 2001 6410 6417
11. D.V. Havlir, N.S. Hellmann, C.J. Petropoulos, J.M. Whitcomb, A.C. Collier, and M.S. Hirsch Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens JAMA 283 2 2000 229 234
12. A. Ibanez, T. Puig, J. Elias, B. Clotet, L. Ruiz, and M.A. Martinez Quantification of integrated and total HIV-1 DNA after long-term highly active antiretroviral therapy in HIV-1-infected patients AIDS 13 9 1999 1045 1049
13. M.F. Kavlick, T. Shirasaka, E. Kojima, J.M. Pluda, F. Hui Jr., and R. Yarchoan Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (-)-2′,3′-dideoxy-3′-thiacytidine Antiviral Res 28 2 1995 133 146
14. S. Little Amplification refractory mutation system (ARMS) analysis of any point mutation N.C. Dracopoli J.L. Haines B.R. Korf C.C. Morton C.E. Seidman J.G. Seidman D.R. Smith Current protocols in human genetics 1995 J Wiley & Sons New York 9.8.1-12
15. L.M. Mansky, and H.M. Temin Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase J Virol 69 8 1995 5087 5094
16. V. Miller, T. Stark, A.E. Loeliger, and J.M. Lange The impact of the M184V substitution in HIV-1 reverse transcriptase on treatment response HIV Med 3 2 2002 135 145
17. D. Nadal, F. Steiner, J.J. Cheseaux, C.A. Lazarevitch, C. Aebi, and C. Kind Long-term responses to treatment including ritonavir or nelfinavir in HIV-1-infected children. Pediatric AIDS Group of Switzerland Infection 28 5 2000 287 296
18. R.E. Nettles, T.L. Kieffer, R.P. Simmons, J. Cofrancesco Jr., R.D. Moore, and J.E. Gallant Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy Clin Infect Dis 39 7 2004 1030 1037
19. C.R. Newton, A. Graham, L.E. Heptinstall, S.J. Powell, C. Summers, and N. Kalsheker Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS) Nucleic Acids Res 17 7 1989 2503 2516
20. Observations of HIV-1 genotypic drug resistance in a trial of four reverse transcriptase inhibitors (Quattro Trial). Antivir Ther 2002;7(1):11-20.
21. F.J. Palella Jr., J.S. Chmiel, A.C. Moorman, and S.D. Holmberg Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients AIDS 16 12 2002 1617 1626
22. N.T. Parkin, S.G. Deeks, M.T. Wrin, J. Yap, R.M. Grant, and K.H. Lee Petropoulos CJ. Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatment-experienced patients AIDS 14 18 2000 2877 2887
23. A.S. Perelson, P. Essunger, and D.D. Ho Dynamics of HIV-1 and CD4+ lymphocytes in vivo AIDS 11 Suppl. A 1997 S17 S24
24. T. Pierson, J. McArthur, and R.F. Siliciano Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy Annu Rev Immunol 18 2000 665 708
25. R.R. Russell, M.I. Bowmer, C. Nguyen, and M.D. Grant HIV-1 DNA burden in peripheral blood CD4+ cells influences disease progression, antiretroviral efficacy, and CD4+ T-cell restoration Viral Immunol 14 4 2001 379 389
26. M.E. Sharkey, I. Teo, T. Greenough, N. Sharova, K. Luzuriaga, and J.L. Sullivan Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy Nat Med 6 1 2000 76 81
27. J. Servais, J.C. Schmit, V. Arendt, C. Lambert, T. Staub, and I. Robert Three-year effectiveness of highly active antiretroviral treatment in the Luxembourg HIV cohort HIV Clin Trials 1 2 2000 17 24
28. J.D. Siliciano, J. Kajdas, D. Finzi, T.C. Quinn, K. Chadwick, and JB. Margolick Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells Nat Med 9 6 2003 727 728
29. M. Tisdale, S.D. Kemp, N.R. Parry, and B.A. Larder Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase Proc Natl Acad Sci USA 90 12 1993 5653 5656
30. P.R. Wenham, C.R. Newton, and W.H. Price Analysis of apolipoprotein E genotypes by the amplification refractory mutation system Clin Chem 37 11 1991 241 244
31. J.M. Whitcomb, N.T. Parkin, C. Chappey, N.S. Hellmann, and C.J. Petropoulos Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates J Infect Dis 188 7 2003 992 1000
32. M. Zaccarelli, C.F. Perno, F. Forbici, A. Cingolani, G. Liuzzi, and A. Bertoli Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation Antivir Ther 8 1 2003 51 56